Welcome to our dedicated page for Xcel Brands SEC filings (Ticker: XELB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xcel Brands Inc. filings document the regulatory record for a media and consumer-products brand manager whose business uses licensing, design, marketing, sourcing and service arrangements. Its Securities Act registration statements describe common stock offerings, resale mechanics, purchase-agreement structures, business risks and the company’s smaller-reporting-company status.
Recent 8-K filings cover material agreements, debt obligations, amendments to loan and security agreements, senior secured notes, cash-collateral and covenant terms, equity financing arrangements, and the sale of the Judith Ripka brand assets. Other filings include Form 12b-25 notices for periodic-report timing, together with disclosures on subsidiaries, collateral, capital structure and governance matters tied to the company’s operating and financing arrangements.
On 17 June 2025, Xcel Brands, Inc. (NASDAQ: XELB) convened a Special Meeting where shareholders voted on two critical corporate actions. A quorum of 1,637,039 shares (≈68.6% of the 2,386,325 outstanding) was present.
1. Warrant Exercise Proposal. Shareholders approved, under Nasdaq Rule 5635, the issuance of common stock exceeding 19.99% of outstanding shares upon exercise of refinancing-related warrants. The motion passed with 1,020,922 votes for, 5,503 against, 540 abstentions and 610,074 broker non-votes. The approval removes a regulatory barrier and allows the company to complete its April 21, 2025 refinancing terms.
2. Reverse Stock Split Proposal. Investors authorised the Board, at its discretion, to execute a reverse split between 1-for-2 and 1-for-5 any time before 25 March 2026. This measure passed decisively with 1,613,691 votes for, 23,019 against and 329 abstentions. The flexibility could help Xcel maintain Nasdaq listing standards by boosting its per-share price.
No additional matters required a vote. Collectively, the approvals provide management with enhanced capital-raising and compliance tools, though they introduce potential dilution and share-count reduction depending on future execution.